Highlighting Inhalation Development at Drug Delivery to the Lungs (DDL) Conference
We will attend the Drug Delivery to the Lungs (DDL) Conference, 11 - 13th December 2019, Edinburgh, UK. Meet with us to discuss your development challenges for pulmonary and nasal drug delivery.
The Drug Delivery to the Lungs Conference (DDL) is Europe’s premier conference and industry exhibition dedicated to pulmonary and nasal drug delivery. The conference will cover some of the major issues for these product types, including; new formulations to treat unmet respiratory needs, including cystic fibrosis, connected & smart devices and advanced analytical techniques supporting inhaler development.
We are delighted to announce that we are platinum DDL sponsors this year and during the conference, our team of experts will be available to discuss your inhalation product development, inhalation product testing, formulation development or stability testing challenges. Contact our team now to arrange a meeting at our stand.
The Impact of Dry Powder Inhaler Performance of Testing Using Pharmacopeial Methodology Compared to More Realistic Testing Conditions
Monbi Chakma1, Mark Parry2 & Professor Ben Forbes1
1 Department of Pharmacy, King’s College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
2 Intertek-Melbourn Scientific Limited, Saxon Way, Melbourn, SG8 6DN, United Kingdom.
Investigation of DPI Particle Microstructure by MDRS to Explain Differences Observed in NGI Results Between Equivalent Products
Daniella Davies1, Mark Copley2, Deborah Huck-Jones3, Mervin Ramjeeawon1, Chris Vernall1, Anna Sipitanou2, Robert Taylor3, Teresa Iley1
1 Intertek Melbourn, Saxon Way, Melbourn, Royston, SG8 6DN, UK
2 Copley Scientific Ltd., Colwick Quays Business Park, Private Road No. 2, Nottingham, NG4 2JY, UK
3 Malvern Panalytical Ltd, Grovewood Rd, Malvern Worcestershire WR14 1XZ, UK
Modifications to an inhaler device to aid the interpretation of clinical trial data
George Bostock1, Tom Lawrie-Fussey1, Alison Hart1, Neil McCarragher1, David Harris1, James Baker1, Mark Parry2 & Ben Crundwell1
1 Cambridge Design Partnership, Church Road, Toft, Cambridge, CB23 2RF, UK
2 Intertek Melbourn, Saxon Way, Melbourn, Royston, SG8 6DN, UK
Our OINDP Development Expertise
Our experts provide integrated OINDP development and testing services for both small molecules and biologics through its centres of excellence across Europe. We provide critical performance and quality testing such as laser particle sizing, aerodynamic particle size distribution (APSD) by impaction (ACI, NGI) and spray pattern/plume geometry. Intertek’s integrated formulation and analytical teams carry out early stage pre-formulation support, solubility screening, drug-excipient compatibility, stability testing and device selection support. For large molecule development, comprehensive protein characterisation services supported by forced degradation and stability monitoring for the protein’s structure and bioactivity throughout formulation and storage can also be provided. Interaction with the device and closure systems are evaluated through comprehensive extractable and leachable testing and toxicological assessments.
WEBINAR RECORDING: New Strategies for Optimizing Biologic Formulations
WEBINAR RECORDING: A Review of In-vitro Testing for Bioequivalence of Nasal Drug Products
WEBINAR RECORDING: Formulation and Manufacturing Approaches for Nasal Drug Products
WEBINAR RECORDING: Stability Programs for Orally Inhaled or Nasal Drug Products
Need help or have a question?